Pidomod (CAS 121808-62-6), also known as primo, spectrum leyi, is an immunomodulator, suitable for patients with low immune function of the body, and can be used to prevent acute infection, shorten the course of disease, reduce the severity of the disease, can be used as an auxiliary drug during the acute infection period.Mainly used in children recurrent respiratory tract infection, urinary tract infection (urinary tract infection), chronic bronchitis also has therapeutic effect, to the virus.Influenza and viral herpes are effective.It can also be used for infection caused by pneumococcal pneumonia and escherichia coli, pseudomonas aeruginosa and proteus.
This report contains market size and forecasts of Pidotimod in global, including the following market information:
Global Pidotimod Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Pidotimod Market Sales, 2017-2022, 2023-2028, (KG)
Global top five Pidotimod companies in 2021 (%)
The global Pidotimod market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Piece Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Pidotimod include Active Peptide Company, Reco Tech, Manus Aktteva Biopharma, Joyochem, Changzhou Yinsheng Pharmaceutical and Dr. Reddy’s, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Pidotimod manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pidotimod Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (KG)
Global Pidotimod Market Segment Percentages, by Type, 2021 (%)
Piece
Oral Liquid
Capsule
Particles
Other
Global Pidotimod Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (KG)
Global Pidotimod Market Segment Percentages, by Application, 2021 (%)
Gynecological Infection
Urinary Tract Infection (UTI)
Respiratory Infections
Other
Global Pidotimod Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (KG)
Global Pidotimod Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pidotimod revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Pidotimod revenues share in global market, 2021 (%)
Key companies Pidotimod sales in global market, 2017-2022 (Estimated), (KG)
Key companies Pidotimod sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Active Peptide Company
Reco Tech
Manus Aktteva Biopharma
Joyochem
Changzhou Yinsheng Pharmaceutical
Dr. Reddy’s